Skip to content
stoqly
en

Languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Allogene Therapeutics, Inc.

ALLO Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2018–FY2025

Allogene Therapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.

Download report 3-page PDF: the company, its results and charts with peers.

Last close Β· Oct 23, 2026

$1.25

0.0%

What Allogene Therapeutics, Inc. does

ALLO Β· Biological Products, (No Diagnostic Substances)

From its latest annual report

No business description yet.

Filing details

Legal name
Allogene Therapeutics, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K Β· Mar 12, 2026
Accession Β· CIK
0001628280-26-017242 Β· 0001737287

KIRA’s summary AI analyst

Hi! I read Allogene Therapeutics, Inc.’s latest annual report (fiscal 2025). Here is what stands out:

4 to watch

Allogene Therapeutics, Inc. in 30 seconds

Good So-so Weak

Weak

Are sales growing?

βˆ’100.0%

No. Sales fell 100.0% last year.

Weak

Does it make a profit?

βˆ’$191M

No. It lost money last year.

Weak

How healthy are the accounts?

2 / 7

Weak. It passes 2 of 7 health tests.

For information

How is the share priced?

β€”

No P/E: it made no profit over the last four quarters.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
$411M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
β€”
On βˆ’$0.67 EPS (TTM)

Revenue

Total sales reported in the income statement.

KIRA Β· Allogene Therapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.

See the full section β†’

Operating margin

Operating income as a share of revenue.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Allogene Therapeutics, Inc. lost $191M in fiscal 2025.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was βˆ’$150M in fiscal 2025, β€” of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

See the full section β†’
Charts by

Sales and profit

Is it selling more, and how much does it keep?

Results dates

In plain words: Every quarter, companies publish how much they sold and earned. These are the days Allogene Therapeutics, Inc. did it, and the next one. Share prices often move a lot on those days.

Next results

November 5, 2026

Thursday Β· in 10 days

Time
Time not announced
Covers
Period ended Sep 30, 2026
Expected EPS
βˆ’$0.13
Source
Earnings calendar
See who else reports that week β†’
Date Results for Time Source
Aug 12, 2026 Q2 '26 After the market closes 8-K β†—
May 12, 2026 Q1 '26 Time not announced 8-K β†—
Mar 12, 2026 Q4 '25 After the market closes 8-K β†—
Nov 6, 2025 Q3 '25 After the market closes 8-K β†—
Aug 13, 2025 Q2 '25 After the market closes 8-K β†—
May 13, 2025 Q1 '25 After the market closes 8-K β†—
Mar 13, 2025 Q4 '24 After the market closes 8-K β†—
Nov 7, 2024 Q3 '24 After the market closes 8-K β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

Revenue and margins

KIRA Β· Allogene Therapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

Revenue

Margins, % of revenue

Gross Operating Net FCF

Margins, % of revenue

Gross Operating Net FCF

Net income and earnings per share

KIRA Β· Allogene Therapeutics, Inc. lost $191M in fiscal 2025.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

Net income

Diluted EPS

Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

KIRA Β· Free cash flow was βˆ’$150M in fiscal 2025, β€” of revenue.

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

Dividends, buybacks and share count

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

Insider trades

KIRA Β· No open-market insider trades in the last 12 months.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

β€”

$0.0M

No open-market insider trades in the last 12 months.

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

Cash, debt and the ratios that show how comfortably Allogene Therapeutics, Inc. can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $457M$517M$449M$292M$250M
Interest coverage β€”β€”β€”βˆ’1,509.4xβˆ’194.7x
Current ratio 9.8x9.8x12.4x8.5x7.9x
Quick ratio 9.8x9.8x12.4x8.5x7.9x
Total assets $1.1B$822M$643M$549M$416M
Total liabilities $126M$155M$131M$127M$123M
Shareholders' equity $925M$667M$512M$422M$293M
Net debt (βˆ’ = net cash) β€”β€”β€”β€”β€”

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

Piotroski F-score

KIRA Β· Allogene Therapeutics, Inc. passes 2 of 7 financial health tests (Piotroski F-score).

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Cash from operations is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Return on assets rose β€” βœ“ βœ• βœ“ βœ• βœ• βœ“ βœ“
Cash from operations exceeds net income βœ“ βœ“ βœ“ βœ• βœ“ βœ“ βœ“ βœ“
Debt fell relative to assets β€” β€” β€” β€” β€” β€” β€” β€”
Current ratio rose β€” βœ“ βœ• βœ“ βœ“ βœ“ βœ• βœ•
Share count didn't rise β€” βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Gross margin rose β€” β€” β€” β€” β€” β€” β€” β€”
Revenue rose relative to assets β€” β€” βœ• βœ“ βœ• βœ• βœ• βœ•
F-score β€” / 3β€” / 61 / 73 / 72 / 72 / 72 / 72 / 7
Accruals ratio βˆ’21.6%βˆ’6.3%βˆ’20.7%0.2%βˆ’12.8%βˆ’12.2%βˆ’9.6%βˆ’8.6%
Altman Z'' 11.608.427.896.450.68βˆ’2.92βˆ’7.45βˆ’13.10

All figures

Every number, year by year.

8 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue β€” $0.0M $0.0M $114M $0.2M $0.1M $0.0M $0.0M
Research and development $152M $145M $193M $220M $256M $243M $192M $150M
Operating income βˆ’$193M βˆ’$202M βˆ’$258M βˆ’$180M βˆ’$336M βˆ’$328M βˆ’$273M βˆ’$209M
Interest expense $3.4M $0.0M $0.0M β€” β€” $0.0M $0.2M $1.1M
Pretax income βˆ’$212M βˆ’$185M βˆ’$250M βˆ’$257M β€” βˆ’$327M βˆ’$257M βˆ’$191M
Income tax βˆ’$0.1M βˆ’$0.3M $0.0M $0.0M $0.0M $0.0M $0.4M $0.0M
Net income βˆ’$212M βˆ’$185M βˆ’$316M βˆ’$182M βˆ’$340M βˆ’$327M βˆ’$258M βˆ’$191M
Diluted EPS βˆ’$7.31 βˆ’$1.83 βˆ’$2.63 βˆ’$1.34 βˆ’$2.38 βˆ’$2.09 βˆ’$1.32 βˆ’$0.87
Diluted shares 0.03B 0.10B 0.12B 0.14B 0.14B 0.16B 0.19B 0.22B
Cash flow
Cash from operations βˆ’$44.7M βˆ’$137M βˆ’$115M βˆ’$185M βˆ’$221M βˆ’$238M βˆ’$200M βˆ’$149M
Capital expenditure $3.2M $50.8M $66.0M $21.4M $5.2M $1.5M $0.7M $0.4M
Free cash flow βˆ’$47.9M βˆ’$188M βˆ’$181M βˆ’$206M βˆ’$226M βˆ’$239M βˆ’$201M βˆ’$150M
Depreciation and amortization $1.0M $4.6M $7.4M $10.5M $14.3M $14.2M $13.6M $12.4M
Stock-based compensation $18.6M $46.1M $65.3M $80.8M $83.6M $66.0M $51.7M $37.6M
Balance sheet
Cash and short-term investments $459M $531M $828M $457M $517M $449M $292M $250M
Current assets $468M $545M $845M $471M $529M $459M $303M $258M
Current liabilities $29.5M $33.1M $94.3M $47.9M $53.7M $37.1M $35.5M $32.5M
Property and equipment, net $8.6M $56.4M $119M $123M $113M $99.5M $86.1M $72.8M
Intangible assets $0.8M $0.2M $0.0M β€” β€” β€” β€” β€”
Total assets $774M $718M $1.2B $1.1B $822M $643M $549M $416M
Total liabilities $70.7M $88.8M $148M $126M $155M $131M $127M $123M
Preferred stock $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Shareholders' equity $703M $629M $1.0B $925M $667M $512M $422M $293M
Margins
Operating margin β€” β€” β€” βˆ’157.9% βˆ’215,087.2% βˆ’344,986.3% βˆ’1,241,813.6% β€”
EBITDA margin β€” β€” β€” βˆ’148.7% βˆ’205,920.5% βˆ’330,040.0% βˆ’1,179,818.2% β€”
Net margin β€” β€” β€” βˆ’159.6% βˆ’218,214.1% βˆ’344,489.5% βˆ’1,170,863.6% β€”
FCF margin β€” β€” β€” βˆ’180.8% βˆ’144,685.9% βˆ’251,841.1% βˆ’913,609.1% β€”
Returns
Return on capital employed βˆ’25.9% βˆ’29.5% βˆ’22.8% βˆ’18.0% βˆ’43.7% βˆ’54.1% βˆ’53.2% βˆ’54.6%
Return on equity βˆ’30.1% βˆ’27.7% βˆ’38.5% βˆ’18.8% βˆ’42.8% βˆ’55.5% βˆ’55.1% βˆ’53.4%
Return on assets βˆ’27.3% βˆ’24.8% βˆ’32.5% βˆ’16.0% βˆ’36.4% βˆ’44.7% βˆ’43.2% βˆ’39.6%
Return on tangible equity βˆ’30.1% βˆ’29.4% βˆ’31.2% βˆ’19.7% βˆ’51.0% βˆ’63.9% βˆ’61.0% βˆ’65.3%
Growth
Revenue growth β€” β€” β€” β€” βˆ’99.9% βˆ’39.1% βˆ’76.8% βˆ’100.0%
Share count change β€” 249.1% 19.1% 12.8% 5.4% 9.6% 24.1% 13.2%
Financial health
Interest coverage βˆ’57.4x β€” β€” β€” β€” β€” βˆ’1,509.4x βˆ’194.7x
Current ratio 15.9x 16.5x 9.0x 9.8x 9.8x 12.4x 8.5x 7.9x
Quick ratio 15.9x 16.5x 9.0x 9.8x 9.8x 12.4x 8.5x 7.9x
Capital allocation
Capex / revenue β€” β€” β€” 18.8% 3,327.6% 1,595.8% 3,154.5% β€”
Stock comp / revenue β€” β€” β€” 70.8% 53,589.7% 69,422.1% 235,195.5% β€”
Quality scores
Piotroski F-score β€” β€” 1.0 3.0 2.0 2.0 2.0 2.0
Altman Z'' 11.6 8.4 7.9 6.4 0.7 βˆ’2.9 βˆ’7.5 βˆ’13.1
Accruals ratio βˆ’21.6% βˆ’6.3% βˆ’20.7% 0.2% βˆ’12.8% βˆ’12.2% βˆ’9.6% βˆ’8.6%

Source: SEC EDGAR XBRL filings (CIK 0001737287). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open